Literature DB >> 10681363

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

L M Demeter1, R W Shafer, P M Meehan, J Holden-Wiltse, M A Fischl, W W Freimuth, M F Para, R C Reichman.   

Abstract

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10681363      PMCID： PMC89771          DOI： 10.1128/AAC.44.3.794-797.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

2.  Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.

Authors:  R W Shafer; J A Eisen; T C Merigan; D A Katzenstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.

Authors:  M F Para; P Meehan; J Holden-Wiltse; M Fischl; G Morse; R Shafer; L M Demeter; K Wood; T Nevin; N Virani-Ketter; W W Freimuth
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.

Authors:  J H Nunberg; W A Schleif; E J Boots; J A O'Brien; J C Quintero; J M Hoffman; E A Emini; M E Goldman
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.

Authors:  F B Hollinger; J W Bremer; L E Myers; J W Gold; L McQuay
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

6.  A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.

Authors:  T J Dueweke; T Pushkarskaya; S M Poppe; S M Swaney; J Q Zhao; I S Chen; M Stevenson; W G Tarpley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

7.  U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.

Authors:  T J Dueweke; S M Poppe; D L Romero; S M Swaney; A G So; K M Downey; I W Althaus; F Reusser; M Busso; L Resnick
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

8.  A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.

Authors:  M S Saag; E A Emini; O L Laskin; J Douglas; W I Lapidus; W A Schleif; R J Whitley; C Hildebrand; V W Byrnes; J C Kappes
Journal:  N Engl J Med       Date:  1993-10-07       Impact factor: 91.245

9.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

10.  Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Authors:  A J Japour; D L Mayers; V A Johnson; D R Kuritzkes; L A Beckett; J M Arduino; J Lane; R J Black; P S Reichelderfer; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
View more
  25 in total

1.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

Review 3.  Delavirdine: clinical pharmacokinetics and drug interactions.

Authors:  J Q Tran; J G Gerber; B M Kerr
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

Review 5.  Delavirdine: a review of its use in HIV infection.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 6.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 7.  The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection.

Authors:  S Maddocks; D Dwyer
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

8.  The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.

Authors:  J Wang; C Dykes; R A Domaoal; C E Koval; R A Bambara; L M Demeter
Journal:  Virology       Date:  2006-02-28       Impact factor: 3.616

9.  The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.

Authors:  P Gerondelis; R H Archer; C Palaniappan; R C Reichman; P J Fay; R A Bambara; L M Demeter
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

10.  Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.

Authors:  Paula Ordonez; Takayuki Hamasaki; Yohei Isono; Norikazu Sakakibara; Masahiro Ikejiri; Tokumi Maruyama; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.